57.87MMarket Cap-449P/E (TTM)
0.500High0.480Low98.80KVolume0.500Open0.485Pre Close48.08KTurnover0.09%Turnover RatioLossP/E (Static)118.11MShares3.33052wk High2.61P/B56.56MFloat Cap0.42052wk Low--Dividend TTM115.44MShs Float35.200Historical High--Div YieldTTM4.13%Amplitude0.420Historical Low0.486Avg Price1Lot Size
Gritstone Bio Stock Forum
spike and down again, volume slowly building up
NEWS
Gritstone bio Highlights the Durability and Potential Broad Utility of its Self-amplifying mRNA (samRNA) COVID-19 Vaccine at ESCMID Global 2024
NEWS
Nature Medicine Publishes Interim Results from Gritstone bio’s Phase 1/2 Study of “Off-the-Shelf” Neoantigen Vaccine Platform (SLATE)
-- Paper details vaccine design optimization process of Gritstone’s “off-the-shelf” or shared neoantigen vaccine platform, SLATE --
-- Discovery of a novel immunodominance hierarchy of tumor neoantigens (including KRAS) enabled the development of a more potent, KRAS-specific vaccine candidate (SLATE-KRAS) being studied by Steven A. ...
No comment yet